Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy

Abstract

Background. Systemic immunity and inflammation indexes (SI) derived from blood cells have gained increasing attention in clinical oncology as potential biomarkers that are associated with survival. Materials and methods. We tested 12 different SI using blood tests from patients with isocitrate dehydrogenase 1 and 2 wild-type glioblastomas, treated with radio-chemotherapy. The primary endpoint was their overall survival. Results. A total of 77 patients, comprising 43 males and 34 females, with a median age of 64 years (age range 26–84), who were treated between October 2010 and July 2020, were included in the present analysis (approved by a local ethics committee). In the univariate Cox regression analysis, all the indexes except two showed a statistically significant impact on OS. In the multivariate Cox regression analysis, neutrophil × platelet × leukocyte/(lymphocyte × monocyte) (NPW/LM) and neutrophil × platelet × monocyte/lymphocyte (NPM/L) maintained their statistically significant impact value. Conclusions. This univariate analysis confirms the potential of systemic inflammation indexes in patients with glioblastoma, while the multivariate analysis verifies the prognostic value of NPW/LM and NPM/L.

Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma

“…Current approaches in immunotherapy, e.g., by personalized peptide vaccination, can lead to an increased infiltration of CD8-positive T cells and increased immunogenicity [ 65 ]. Moreover, systemic immunosuppressive and inflammation markers can be influenced by novel therapeutic options as well [ 66 , 67 , 68 , 69 ].…”

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

“…This pain sensitivity modulation is another possible mechanism. Also, the headache may be aggravated or modified by promoting systemic inflammation due to GBM [10], which is related to GBM prognosis.…”

Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis

“…Duplicate studies were excluded, and conference abstracts or studies lacking sufficient data were excluded after full-text evaluation. Five studies that enrolled 788 patients were included in the final metaanalysis [20][21][22][23]26]. The selection process of the meta-analysis is shown in Supplementary Figure S1.…”

“…The systemic immune-inflammation index (SII) [17], a novel inflammatory biomarker calculated by platelet count*neutrophil count/lymphocyte count, has been determined to be related to worse outcomes in many cancer patients, including breast cancer [18], hepatocellular carcinoma [19] and glioma [20]. Two recent studies reported that a higher SII was associated with a worse outcome in the GBM cohort [21,22]. However, the prognostic value of the SII is still controversial.…”